A Multicenter, Randomized Controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of ZVS101e Administered as a Single Subretinal Injection in Subjects With Bietti's Crystalline Dystrophy (BCD)
Latest Information Update: 07 Jan 2025
Price :
$35 *
At a glance
- Drugs ZVS 101e (Primary)
- Indications Bietti crystalline dystrophy
- Focus Registrational; Therapeutic Use
- Sponsors Chigenovo
- 25 Dec 2024 New trial record